XXXX.png
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
17 déc. 2024 06h30 HE | Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
XXXX.png
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
22 nov. 2024 16h30 HE | Silexion Therapeutics Corp
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
XXXX.png
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
20 nov. 2024 08h30 HE | Silexion Therapeutics Corp
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,...